[(18)F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

BACKGROUND: Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [(18)F]FDG PET radiomics signature (iRADIOMICS) predicts resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentinuzzi, Damijan, Vrankar, Martina, Boc, Nina, Ahac, Valentina, Zupancic, Ziga, Unk, Mojca, Skalic, Katja, Zagar, Ivana, Studen, Andrej, Simoncic, Urban, Eickhoff, Jens, Jeraj, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409607/
https://www.ncbi.nlm.nih.gov/pubmed/32726293
http://dx.doi.org/10.2478/raon-2020-0042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409607/
https://www.ncbi.nlm.nih.gov/pubmed/32726293
http://dx.doi.org/10.2478/raon-2020-0042

Ejemplares similares